{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:23:37Z","timestamp":1768811017541,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019708","name":"UroGen Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.urology.2024.07.017","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T01:05:32Z","timestamp":1721264732000},"page":"166-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Low-grade Urothelial Carcinoma Recurs at a Tempo that Naturally Accelerates Over Time"],"prefix":"10.1016","volume":"193","author":[{"given":"Alex","family":"Sankin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise-Rae","family":"Cherrill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca H.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice P.","family":"Zeegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilir","family":"Agalliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2024.07.017_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2490-14-5","article-title":"Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression","volume":"14","author":"Kobayashi","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib2","doi-asserted-by":"crossref","first-page":"796.e1","DOI":"10.1016\/j.urolonc.2020.04.026","article-title":"Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members","volume":"38","author":"Matulay","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2024.07.017_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.urology.2019.04.036","article-title":"Overuse of cystoscopic surveillance among patients with low-risk non-muscle-invasive bladder cancer - a national study of patient, provider, and facility factors","volume":"131","author":"Han","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.07.017_bib4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1464-410X.2009.08849.x","article-title":"The west midlands bladder cancer prognosis programme: rationale and design","volume":"105","author":"Zeegers","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2024.07.017_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37494","article-title":"Selenium and vitamin E for prevention of non\u2013muscle-invasive bladder cancer recurrence and progression: a randomized clinical trial","volume":"6","author":"Bryan","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.urology.2024.07.017_bib6","first-page":"466","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur\u00a0Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2013.08.034","article-title":"Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder","volume":"65","author":"Rieken","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2016.07.063","article-title":"Long-term bladder and upper urinary tract follow-up recurrence and progression rates of G1-2 non-muscle-invasive urothelial carcinoma of the bladder","volume":"100","author":"Golabesk","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.07.017_bib10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00005392-199909010-00019","article-title":"Recurrence and progression in low grade papillary urothelial tumors","volume":"162","author":"Holmang","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000020010","article-title":"Late recurrence and progression after a long tumor-free period in primary Ta and T1 bladder cancer","volume":"36","author":"Fujii","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13193-018-0728-8","article-title":"Low-grade, multiple, Ta non-muscle-invasive bladder tumors: tumor recurrence and worsening progression","volume":"9","author":"Nerli","year":"2018","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.urology.2024.07.017_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1464-410x.2000.00547.x","article-title":"Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression","volume":"85","author":"Zieger","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2024.07.017_bib14","first-page":"40","article-title":"The factors affecting recurrence and prognosis in patients with low-grade stage Ta bladder cancer","volume":"20","author":"Ozbek","year":"2021","journal-title":"Bull\u00a0Urooncol"},{"key":"10.1016\/j.urology.2024.07.017_bib15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0022-5347(17)45923-4","article-title":"Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection","volume":"135","author":"Fitzpatrick","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211721","article-title":"Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non\u2013muscle-invasive bladder cancer and with low and intermediate EORTC-risk score","volume":"14","author":"Simon","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2024.07.017_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1442-2042.2006.01386.x","article-title":"Recurrence pattern for superficial bladder cancer","volume":"13","author":"Akagashi","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1046\/j.1464-410x.1999.00078.x","article-title":"The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience","volume":"83","author":"Haukaas","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2024.07.017_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0302-2838(03)00052-6","article-title":"Long-term surveillance of bladder tumours: current practice in the United Kingdom and Ireland","volume":"43","author":"Wazait","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib20","first-page":"785","article-title":"A rational risk assessment for intravesical recurrence in primary low-grade Ta bladder cancer: a\u00a0retrospective analysis of 245 cases","volume":"8","author":"Akitake","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.urology.2024.07.017_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.10822","article-title":"Patterns of multiple recurrences of superficial (Ta\/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors","volume":"95","author":"Yan","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2024.07.017_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.urology.2009.08.082","article-title":"Complete transurethral resection of bladder tumor\": are the guidelines being followed?","volume":"75","author":"Adiyat","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2024.07.017_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.05.009","article-title":"Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy","volume":"40","author":"Kukreja","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2024.07.017_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2017.07.016","article-title":"The burden of cystoscopic bladder cancer surveillance: anxiety, discomfort, and patient preferences for decision making","volume":"108","author":"Koo","year":"2017","journal-title":"Urology"},{"issue":"3 Suppl","key":"10.1016\/j.urology.2024.07.017_bib25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/1097-0142(19870801)60:3+<553::AID-CNCR2820601519>3.0.CO;2-3","article-title":"Sexuality and fertility in urologic cancer patients","volume":"60","author":"Schover","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2024.07.017_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bja.2018.05.060","article-title":"Association between exposure to anaesthesia and surgery and long-term cognitive trajectories in older adults: report from the Mayo Clinic Study of Aging","volume":"121","author":"Schulte","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.urology.2024.07.017_bib27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urology.2024.07.017_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urology.2024.07.017_bib29","first-page":"723","article-title":"Recurrent Ta low-grade non-muscle-invasive bladder cancer: what are the options?","volume":"2","author":"Roupr\u00eat","year":"2019","journal-title":"Eur\u00a0Urol\u00a0Oncol"},{"key":"10.1016\/j.urology.2024.07.017_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JU.0000000000001689","article-title":"Surveillance intensity in intermediate risk, nonmuscle invasive bladder cancer: revisiting the optimal timing and frequency of cystoscopy","volume":"206","author":"Bhat","year":"2021","journal-title":"J Urol"},{"issue":"2 Pt 1","key":"10.1016\/j.urology.2024.07.017_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.urology.2024.07.017_bib32","first-page":"504","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non\u2013muscle-invasive bladder cancer (IR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: Cohort 3 interim analysis","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.urology.2024.07.017_bib33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JU.0000000000002186","article-title":"Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial","volume":"207","author":"Chevli","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib34","first-page":"619","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urology.2024.07.017_bib36","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.euf.2017.09.002","article-title":"Discrepancy between european association of urology guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey","volume":"5","author":"Hendricksen","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2024.07.017_bib37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2020.06.051","article-title":"Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from scotland's quality performance indicators programme","volume":"78","author":"Mariappan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2024.07.017_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0391560319899303","article-title":"How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices","volume":"87","author":"Sountoulides","year":"2020","journal-title":"Urologia"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524005727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524005727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:13:48Z","timestamp":1731629628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429524005727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"alternative-id":["S0090429524005727"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2024.07.017","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-grade Urothelial Carcinoma Recurs at a Tempo that Naturally Accelerates Over Time","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2024.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}